{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T14:15:23Z","timestamp":1778681723450,"version":"3.51.4"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,1,3]],"date-time":"2026-01-03T00:00:00Z","timestamp":1767398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,3]],"date-time":"2026-01-03T00:00:00Z","timestamp":1767398400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82200149"],"award-info":[{"award-number":["82200149"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81900130"],"award-info":[{"award-number":["81900130"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1007\/s12185-025-04152-4","type":"journal-article","created":{"date-parts":[[2026,1,3]],"date-time":"2026-01-03T08:43:19Z","timestamp":1767429799000},"page":"654-663","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Venetoclax-based combination regimens for therapy-related myeloid neoplasms"],"prefix":"10.1007","volume":"123","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0866-1797","authenticated-orcid":false,"given":"Tongtong","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanglan","family":"Fang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinyan","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haixia","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-3107-9127","authenticated-orcid":false,"given":"Mingzhu","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,3]]},"reference":[{"issue":"20","key":"4152_CR1","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","volume":"127","author":"DA Arber","year":"2016","unstructured":"Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391\u2013405.","journal-title":"Blood"},{"issue":"3","key":"4152_CR2","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1309\/AJCPD85MCOHHCOMQ","volume":"132","author":"M Czader","year":"2009","unstructured":"Czader M, Orazi A. Therapy-related myeloid neoplasms. Am J Clin Pathol. 2009;132(3):410\u201325.","journal-title":"Am J Clin Pathol"},{"issue":"3","key":"4152_CR3","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1002\/ajh.23908","volume":"90","author":"E Hulegardh","year":"2015","unstructured":"Hulegardh E, Nilsson C, Lazarevic V, et al. Characterization and prognostic features of secondary acute myeloid leukemia in a population-based setting: a report from the Swedish Acute Leukemia Registry. Am J Hematol. 2015;90(3):208\u201314.","journal-title":"Am J Hematol"},{"issue":"12","key":"4152_CR4","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1182\/blood.2022016867","volume":"140","author":"H Dohner","year":"2022","unstructured":"Dohner H, Wei AH, Appelbaum FR, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140(12):1345\u201377.","journal-title":"Blood"},{"issue":"31","key":"4152_CR5","doi-asserted-by":"publisher","first-page":"3641","DOI":"10.1200\/JCO.2014.60.0890","volume":"33","author":"LS Granfeldt \u00d8stg\u00e5rd","year":"2015","unstructured":"Granfeldt \u00d8stg\u00e5rd LS, Medeiros BC, Sengel\u00f8v H, et al. Epidemiology and clinical significance of secondary and therapy-related acute myeloid leukemia: a National Population-Based Cohort Study. J Clin Oncol. 2015;33(31):3641\u20139.","journal-title":"J Clin Oncol"},{"issue":"7","key":"4152_CR6","doi-asserted-by":"publisher","first-page":"2137","DOI":"10.1182\/blood-2010-08-301713","volume":"117","author":"S Kayser","year":"2011","unstructured":"Kayser S, D\u00f6hner K, Krauter J, et al. The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML. Blood. 2011;117(7):2137\u201345.","journal-title":"Blood"},{"issue":"4","key":"4152_CR7","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.3324\/haematol.2022.281233","volume":"108","author":"C Nilsson","year":"2023","unstructured":"Nilsson C, Linde F, Huleg\u00e5rdh E, et al. Characterization of therapy-related acute myeloid leukemia: increasing incidence and prognostic implications. Haematologica. 2023;108(4):1015\u201325.","journal-title":"Haematologica"},{"issue":"4","key":"4152_CR8","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1182\/bloodadvances.2021005335","volume":"6","author":"D Mart\u00ednez-Cuadr\u00f3n","year":"2022","unstructured":"Mart\u00ednez-Cuadr\u00f3n D, Meg\u00edas-Vericat JE, Serrano J, et al. Treatment patterns and outcomes of 2310 patients with secondary acute myeloid leukemia: a PETHEMA registry study. Blood Adv. 2022;6(4):1278\u201395.","journal-title":"Blood Adv"},{"issue":"16","key":"4152_CR9","doi-asserted-by":"publisher","first-page":"16929","DOI":"10.1002\/cam4.6322","volume":"12","author":"A Belhabri","year":"2023","unstructured":"Belhabri A, Heiblig M, Morisset S, et al. Clinical outcome of therapy-related acute myeloid leukemia patients. Real-life experience in a University Hospital and a Cancer Center in France. Cancer Med. 2023;12(16):16929\u201344.","journal-title":"Cancer Med"},{"issue":"4","key":"4152_CR10","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.3109\/10428194.2014.946023","volume":"56","author":"Y Chen","year":"2015","unstructured":"Chen Y, Estrov Z, Pierce S, et al. Myeloid neoplasms after breast cancer: \u201ctherapy-related\u201d not an independent poor prognostic factor. Leuk Lymphoma. 2015;56(4):1012\u20139.","journal-title":"Leuk Lymphoma"},{"key":"4152_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2022.103607","volume":"171","author":"SA Strickland","year":"2022","unstructured":"Strickland SA, Vey N. Diagnosis and treatment of therapy-related acute myeloid leukemia. Crit Rev Oncol Hematol. 2022;171:103607.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"10","key":"4152_CR12","doi-asserted-by":"publisher","first-page":"2879","DOI":"10.1007\/s00277-023-05356-6","volume":"102","author":"H Araie","year":"2023","unstructured":"Araie H, Arai Y, Kida M, et al. Poor outcome of allogeneic transplantation for therapy-related acute myeloid leukemia induced by prior chemoradiotherapy. Ann Hematol. 2023;102(10):2879\u201393.","journal-title":"Ann Hematol"},{"issue":"7","key":"4152_CR13","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa2012971","volume":"383","author":"CD DiNardo","year":"2020","unstructured":"DiNardo CD, Jonas BA, Pullarkat V, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020;383(7):617\u201329.","journal-title":"N Engl J Med"},{"issue":"24","key":"4152_CR14","doi-asserted-by":"publisher","first-page":"2137","DOI":"10.1182\/blood.2020004856","volume":"135","author":"AH Wei","year":"2020","unstructured":"Wei AH, Montesinos P, Ivanov V, et al. Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial. Blood. 2020;135(24):2137\u201345.","journal-title":"Blood"},{"issue":"12","key":"4152_CR15","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1038\/s41375-023-02051-3","volume":"37","author":"A Bouchla","year":"2023","unstructured":"Bouchla A, Papageorgiou SG, Symeonidis A, et al. Evaluation of complete response to azacitidine according to the revised International Working Group 2023 response criteria for higher risk MDS. Does it make a difference in patients\u2019 outcome? Leukemia. 2023;37(12):2517\u20139.","journal-title":"Leukemia"},{"issue":"4","key":"4152_CR16","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1002\/ajh.25395","volume":"94","author":"CJ Lee","year":"2019","unstructured":"Lee CJ, Labopin M, Beelen D, et al. Comparative outcomes of myeloablative and reduced-intensity conditioning allogeneic hematopoietic cell transplantation for therapy-related acute myeloid leukemia with prior solid tumor: a report from the acute leukemia working party of the European society for blood and bone marrow transplantation. Am J Hematol. 2019;94(4):431\u20138.","journal-title":"Am J Hematol"},{"issue":"1","key":"4152_CR17","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1038\/s41409-019-0673-3","volume":"55","author":"KS Gatwood","year":"2020","unstructured":"Gatwood KS, Labopin M, Savani BN, et al. Transplant outcomes for patients with therapy-related acute myeloid leukemia with prior lymphoid malignancy: an ALWP of EBMT study. Bone Marrow Transplant. 2020;55(1):224\u201332.","journal-title":"Bone Marrow Transplant"},{"issue":"11","key":"4152_CR18","doi-asserted-by":"publisher","first-page":"923.e1","DOI":"10.1016\/j.jtct.2021.08.010","volume":"27","author":"L Metheny","year":"2021","unstructured":"Metheny L, Callander NS, Hall AC, et al. Allogeneic transplantation to treat therapy-related myelodysplastic syndrome and acute myelogenous leukemia in adults. Transplant Cell Ther. 2021;27(11):923.e1-923.e12.","journal-title":"Transplant Cell Ther"},{"issue":"4","key":"4152_CR19","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1053\/j.seminoncol.2008.04.012","volume":"35","author":"LA Godley","year":"2008","unstructured":"Godley LA, Larson RA. Therapy-related myeloid leukemia. Semin Oncol. 2008;35(4):418\u201329.","journal-title":"Semin Oncol"},{"issue":"3","key":"4152_CR20","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1182\/blood-2003-11-3938","volume":"104","author":"J Offman","year":"2004","unstructured":"Offman J, Opelz G, Doehler B, et al. Defective DNA mismatch repair in acute myeloid leukemia\/myelodysplastic syndrome after organ transplantation. Blood. 2004;104(3):822\u20138.","journal-title":"Blood"},{"issue":"9","key":"4152_CR21","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1182\/blood-2014-11-610543","volume":"125","author":"RC Lindsley","year":"2015","unstructured":"Lindsley RC, Mar BG, Mazzola E, et al. Acute myeloid leukemia ontogeny is defined by distinct somatic mutations. Blood. 2015;125(9):1367\u201376.","journal-title":"Blood"},{"key":"4152_CR22","doi-asserted-by":"publisher","DOI":"10.1200\/PO.22.00400","volume":"7","author":"MD Cantu","year":"2023","unstructured":"Cantu MD, Kanagal-Shamanna R, Wang SA, et al. Clinicopathologic and molecular analysis of normal karyotype therapy-related and de novo acute myeloid leukemia: a multi-institutional study by the bone marrow pathology group. JCO Precis Oncol. 2023;7:e2200400.","journal-title":"JCO Precis Oncol"},{"issue":"1","key":"4152_CR23","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/S1470-2045(16)30626-X","volume":"18","author":"K Takahashi","year":"2017","unstructured":"Takahashi K, Wang F, Kantarjian H, et al. Preleukaemic clonal haemopoiesis and risk of therapy-related myeloid neoplasms: a case-control study. Lancet Oncol. 2017;18(1):100\u201311.","journal-title":"Lancet Oncol"},{"issue":"8","key":"4152_CR24","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1002\/ajh.26589","volume":"97","author":"MV Shah","year":"2022","unstructured":"Shah MV, Chhetri R, Dholakia R, et al. Outcomes following venetoclax-based treatment in therapy-related myeloid neoplasms. Am J Hematol. 2022;97(8):1013\u201322.","journal-title":"Am J Hematol"},{"issue":"7","key":"4152_CR25","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1002\/cncr.34608","volume":"129","author":"E Todisco","year":"2023","unstructured":"Todisco E, Papayannidis C, Fracchiolla N, et al. AVALON: the Italian cohort study on real-life efficacy of hypomethylating agents plus venetoclax in newly diagnosed or relapsed\/refractory patients with acute myeloid leukemia. Cancer. 2023;129(7):992\u20131004.","journal-title":"Cancer"},{"issue":"10","key":"4152_CR26","doi-asserted-by":"publisher","first-page":"e724","DOI":"10.1016\/S2352-3026(20)30210-6","volume":"7","author":"CD DiNardo","year":"2020","unstructured":"DiNardo CD, Maiti A, Rausch CR, et al. 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial. Lancet Haematol. 2020;7(10):e724\u201336.","journal-title":"Lancet Haematol"},{"issue":"15","key":"4152_CR27","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1200\/JCO.18.01600","volume":"37","author":"AH Wei","year":"2019","unstructured":"Wei AH, Strickland SA Jr, Hou JZ, et al. Venetoclax combined with low-dose cytarabine for previously untreated patients with acute myeloid leukemia: results from a phase Ib\/II study. J Clin Oncol. 2019;37(15):1277\u201384.","journal-title":"J Clin Oncol"},{"issue":"15","key":"4152_CR28","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1182\/blood.2023020102","volume":"142","author":"J Xie","year":"2023","unstructured":"Xie J, Bao X, Xue SL, et al. Venetoclax with decitabine as frontline treatment in younger adults with newly diagnosed ELN adverse-risk AML. Blood. 2023;142(15):1323\u20137.","journal-title":"Blood"},{"issue":"22","key":"4152_CR29","doi-asserted-by":"publisher","first-page":"2645","DOI":"10.1182\/blood.2024027217","volume":"145","author":"J Lu","year":"2025","unstructured":"Lu J, Xue SL, Wang Y, et al. Venetoclax and decitabine vs intensive chemotherapy as induction for young patients with newly diagnosed AML. Blood. 2025;145(22):2645\u201355.","journal-title":"Blood"},{"issue":"1","key":"4152_CR30","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1182\/blood-2018-08-868752","volume":"133","author":"CD DiNardo","year":"2019","unstructured":"DiNardo CD, Pratz K, Pullarkat V, et al. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood. 2019;133(1):7\u201317.","journal-title":"Blood"},{"issue":"9","key":"4152_CR31","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.3389\/fonc.2019.01380","volume":"22","author":"MP Chao","year":"2020","unstructured":"Chao MP, Takimoto CH, Feng DD, et al. Therapeutic targeting of the macrophage immune checkpoint CD47 in myeloid malignancies. Front Oncol. 2020;22(9):1380.","journal-title":"Front Oncol"},{"issue":"14","key":"4152_CR32","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1200\/JCO.20.02341","volume":"39","author":"DA Sallman","year":"2021","unstructured":"Sallman DA, DeZern AE, Garcia-Manero G, et al. Eprenetapopt (APR-246) and azacitidine in TP53-mutant myelodysplastic syndromes. J Clin Oncol. 2021;39(14):1584\u201394.","journal-title":"J Clin Oncol"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-025-04152-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-025-04152-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-025-04152-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T13:29:57Z","timestamp":1778678997000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12185-025-04152-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,3]]},"references-count":32,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["4152"],"URL":"https:\/\/doi.org\/10.1007\/s12185-025-04152-4","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,3]]},"assertion":[{"value":"21 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 December 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 January 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was approved by the Committee for the Ethical Review of Research at The First Affiliated Hospital of Soochow University and conducted in accordance with institutional guidelines and the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}